GPT and type 2 diabetes mellitus: In individuals at low risk for MASLD, characterized by the absence of type 2 diabetes mellitus (T2DM) or two or more metabolic risk factors, initial screening consists of a fibrosis-4 (FIB-4) calculation that includes routine serology (AST, ALT, platelets) and age, with subsequent testing every two years if <1.3 (or <2.0 if older than 65 years) [3].